Home
Screener
Insiders
Rankings
Sign in
Create account
Insiders
· Profile
Schobel Alexander Mark
Chief Innovation/Tech Officer at Aquestive Therapeutics. Filing since 21 Nov 2018.
CIK 0001406836
Company
Date
Role
Action
Shares
Amount
Of holding
AQST
Aquestive Therapeutics, Inc.
15 Mar 2024
Chief Innovation/Tech Officer
Sold on a plan
50,000
$300.00K
4.8%
AQST
Aquestive Therapeutics, Inc.
8 Mar 2024
Chief Innovation/Tech Officer
Sold on a plan
25,000
$129.69K
2.3%
AQST
Aquestive Therapeutics, Inc.
8 Jun 2022
Chief Innovation/Tech Officer
Bought
45,871
$44.04K
5.5%
AQST
Aquestive Therapeutics, Inc.
10 Feb 2021
Chief Innovation/Tech Officer
Sold, plan not stated
23,460
$158.36K
2.7%
AQST
Aquestive Therapeutics, Inc.
9 Feb 2021
Chief Innovation/Tech Officer
Sold, plan not stated
11,540
$77.90K
1.3%
AQST
Aquestive Therapeutics, Inc.
8 Feb 2021
Chief Innovation/Tech Officer
Sold, plan not stated
40,792
$265.15K
4.5%
AQST
Aquestive Therapeutics, Inc.
8 May 2020
Chief Innovation/Tech Officer
Sold, plan not stated
40,000
$200.00K
4.2%
AQST
Aquestive Therapeutics, Inc.
29 Apr 2020
Chief Innovation/Tech Officer
Sold, plan not stated
40,000
$180.00K
3.8%
AQST
Aquestive Therapeutics, Inc.
27 Apr 2020
Chief Innovation/Tech Officer
Sold, plan not stated
40,000
$160.00K
4.1%
AQST
Aquestive Therapeutics, Inc.
14 Apr 2020
Chief Innovation/Tech Officer
Sold, plan not stated
40,000
$148.00K
3.9%
AQST
Aquestive Therapeutics, Inc.
10 Dec 2018
Chief Innovation/Tech Officer
Bought
1,000
$7.78K
0.1%
AQST
Aquestive Therapeutics, Inc.
6 Dec 2018
Chief Innovation/Tech Officer
Bought
2,000
$17.38K
0.2%
AQST
Aquestive Therapeutics, Inc.
21 Nov 2018
Chief Innovation/Tech Officer
Bought
1,000
$10.25K
0.1%
13 decisions on file.
